Can lung cancer be considered cured after taking the targeted drug Tepotinib for 6 years?

Lung cancer patients have been taking Tepotinib for six years, but it is not certain whether they have been cured. Targeted therapy is a therapy that targets specific genes. Tepotinib is a drug that targets non-small cell lung cancer with certain METex14 mutations. If a patient has a METex14 mutation in their tumor tissue, taking tepotinib may have a therapeutic effect.

Although targeted therapy can significantly improve the survival and quality of life of patients with lung cancer, not all patients can benefit from targeted therapy. In addition, the effects and duration of targeted therapy vary among individuals, and some patients may require longer treatment to achieve better results. Therefore, if a lung cancer patient takes tepotinib for six years, further examination and evaluation are needed to determine whether the criteria for cure have been met. If the patient's condition is stable and there are no new signs of metastasis or recurrence, maintenance therapy or other treatments can be considered. At the same time, patients also need regular review and monitoring to detect any abnormal changes in time.

The original drug Tepotinib is already on the market in China, but it is not yet eligible for medical insurance. Tepotinib Original drug currently marketed overseas is relatively expensive, and the price of each box of 225mg*30 tablets may be around RMB 80,000 (the price may fluctuate due to exchange rates). There are already generic Tepotinib drugs produced in other countries. The ingredients of these generic drugs are basically the same as those of the original drug, but the price is relatively cheap. For example, the price of 225mg*60 tablets produced by a Laos pharmaceutical factory may be more than 8,000 yuan per box (the price may fluctuate due to exchange rates).